Join us Dec. 1-3 in Nashville for the Digiday Programmatic Marketing Summit
Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
Salesforce’s $5.7 billion Braze deal puts marketers at an ecosystem crossroads
The deal promises faster, more connected marketing, while raising questions about vendor lock-in and how brands stand out as AI automates campaign execution.
AI boosts discovery but reviews still seal the deal, new research shows
ChatGPT is where 16% of shoppers start looking for products. However, only 9% go there to actually buy something.
Future of Marketing Briefing: Advertisers have more ways than ever to choose a holdco, and free holdcos to choose from
Fewer holdcos, more ways to pick one: inside the changing agency pitch.